This study showed that upregulated FAM83A positively correlated with KRAS and mucin 16, cell surface associated (MUC16), and negatively correlated with SMAD4 and titin (TTN) indicating that targeting FAM83A may affect the key gene mutation proteins and further influence immunotherapy responses in PC. Here, KRAS is linked to pachyonychia congenita.